Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Activa Approvable With Conditions; Data Show Dyskinesia Drop Off

This article was originally published in The Gray Sheet

Executive Summary

Medtronic's Activa Parkinson's control therapy system should be indicated for treatment only of "advanced levadopa (L-dopa) responsive" Parkinson's patients, FDA's Neurological Devices Panel recommended at a March 31 meeting in Rockville, Maryland.

You may also be interested in...



Medtronic Activa Postmarket Study On Parkinson’s Will Begin By Summer

Medtronic's 230-patient, three-year post-approval study of its Activa Parkinson's disease neurostimulation therapy will begin enrollment by this summer

Medtronic Activa Postmarket Study On Parkinson’s Will Begin By Summer

Medtronic's 230-patient, three-year post-approval study of its Activa Parkinson's disease neurostimulation therapy will begin enrollment by this summer

Medtronic Garners Bilateral Activa Medicare Reimbursement In 33 States

Medtronic Neurological President Scott Ward acknowledges that current off-label use of the company's Activa deep brain stimulation device for the bilateral treatment of Parkinson's tremor may dampen sales expectations once FDA approves the indication.

Related Content

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel